China's Simcere Reports Slow Q1 Results, But Sales Force Reorganization Could Help Attract New Pharma Partners
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Simcere Pharmaceutical Group, one of the first Chinese domestic pharmaceutical companies to list in the U.S., reported a slow first quarter result due to slower than expected sales of lead product line first-to-market edavarone injection branded Bicun and Yidasheng.